iBio Reports No Revenue and Increased Losses in Latest Financial Filing

iBio, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending December 31, 2025. The company recorded no revenue for the three months ended December 31, 2025, a decrease from $200,000 in the same period the previous year. For the six months ending December 31, 2025, revenue totaled $100,000, down from $200,000 in the prior year. The company's operating expenses surged to approximately $9.4 million for the quarter, compared to $4.6 million in the same quarter of 2024, driven primarily by increased research and development (R&D) costs and general and administrative (G&A) expenses. The net loss for the quarter was $8.99 million, or $0.09 per share, compared to a loss of $4.36 million, or $0.48 per share, in the prior year.

The financial performance reflects a strategic shift in iBio's operations, particularly in its R&D expenditures, which rose to $4.28 million for the quarter, up from $1.88 million a year earlier. This increase is attributed to heightened spending on consultants and services related to the company's preclinical programs, including the development of its lead candidates, IBIO-600 and IBIO-610. G&A expenses also rose significantly, primarily due to a $2.5 million impairment charge related to the indefinite-lived intangible asset, IBIO-101. The total operating expenses for the six months ended December 31, 2025, reached approximately $15.5 million, compared to $8.7 million in the same period of 2024.

Operationally, iBio is advancing its preclinical pipeline, with plans for IBIO-600 to enter Phase 1a clinical trials in the first half of 2026. The company is also focusing on IBIO-610, which is expected to begin human clinical trials in early 2027. iBio's strategic initiatives include leveraging its AI Drug Discovery Platform to develop precision antibodies targeting obesity and cardiometabolic diseases. The company has also engaged in collaborations, notably with AstralBio, to enhance its research capabilities and expedite the development of its therapeutic candidates.

As of December 31, 2025, iBio reported total current assets of approximately $53.4 million, including $28.7 million in cash and cash equivalents and $24 million in investments in debt securities. The company’s total liabilities stood at $7.83 million, with stockholders' equity increasing to $56.56 million from $14.88 million at the end of the previous fiscal period. The increase in equity is largely due to successful capital raises, including a $50 million public offering in August 2025 and a $26 million private placement in January 2026. Despite the current liquidity position, iBio acknowledges ongoing challenges, including a history of losses and negative cash flows, which raise concerns about its ability to continue as a going concern.

Looking ahead, iBio's management believes that its current cash position, bolstered by recent capital raises, is sufficient to fund operations for at least the next 12 months. However, the company remains dependent on successful product development and commercialization to generate future revenue. The strategic focus on advancing its preclinical pipeline and exploring partnerships for its technologies is expected to play a crucial role in its long-term viability and growth.